334 related articles for article (PubMed ID: 20211577)
1. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
2. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic parvoviruses: from basic virology to clinical applications.
Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
[TBL] [Abstract][Full Text] [Related]
4. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
5. [Oncolytic parvoviruses. A new approaches for cancer therapy].
Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
[TBL] [Abstract][Full Text] [Related]
6. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
Hartley A; Kavishwar G; Salvato I; Marchini A
Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment.
Nüesch JP; Lacroix J; Marchini A; Rommelaere J
Clin Cancer Res; 2012 Jul; 18(13):3516-23. PubMed ID: 22566376
[TBL] [Abstract][Full Text] [Related]
8. Double-faceted mechanism of parvoviral oncosuppression.
Geletneky K; Nüesch JP; Angelova A; Kiprianova I; Rommelaere J
Curr Opin Virol; 2015 Aug; 13():17-24. PubMed ID: 25841215
[TBL] [Abstract][Full Text] [Related]
9. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.
Angelova AL; Geletneky K; Nüesch JP; Rommelaere J
Front Bioeng Biotechnol; 2015; 3():55. PubMed ID: 25954743
[TBL] [Abstract][Full Text] [Related]
10. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in the battle between oncolytic viruses and tumours.
Parato KA; Senger D; Forsyth PA; Bell JC
Nat Rev Cancer; 2005 Dec; 5(12):965-76. PubMed ID: 16294217
[TBL] [Abstract][Full Text] [Related]
12. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
[TBL] [Abstract][Full Text] [Related]
13. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
14. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy progress and prospects cancer: oncolytic viruses.
Liu TC; Kirn D
Gene Ther; 2008 Jun; 15(12):877-84. PubMed ID: 18418413
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
18. Novel oncolytic viruses: riding high on the next wave?
Stanford MM; Bell JC; Vähä-Koskela MJ
Cytokine Growth Factor Rev; 2010; 21(2-3):177-83. PubMed ID: 20219409
[TBL] [Abstract][Full Text] [Related]
19. Regression of glioma in rat models by intranasal application of parvovirus h-1.
Kiprianova I; Thomas N; Ayache A; Fischer M; Leuchs B; Klein M; Rommelaere J; Schlehofer JR
Clin Cancer Res; 2011 Aug; 17(16):5333-42. PubMed ID: 21715567
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
Nguyen TL; Wilson MG; Hiscott J
Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]